Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

NCT05125055 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Oral Squamous Cell Carcinoma
Neoadjvant Therapy
Anti-PD-1
Chemotherapy

Interventions

DRUG: Toripalimab (anti-programmed death-1 inhibitor)
DRUG: Albumin paclitaxel
DRUG: Cisplatin
DRUG: Docetaxel
DRUG: 5-Fluorouracil

Sponsor

Shanghai Jiao Tong University School of Medicine